Larimar Therapeutics Reports Promising Results for Friedreich’s Ataxia Treatment
BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) has announced encouraging initial results from its ongoing open-label extension (OLE) study evaluating long-term daily injections of nomlabofusp for Friedreich’s ataxia …
Larimar Therapeutics Reports Promising Results for Friedreich’s Ataxia Treatment Read More